This volume contains a multitude of chapters from pioneers in the area
of genetic mechanisms, targeted therapy, biology and mouse models for
acute myelogenous leukemia. AML is the most common form of leukemia in
adults. It is a deadly form of malignancy, the prognosis for which has
not improved in the last two decades. More importantly, it is a
malignancy that is seen in older adults, therefore the number of cases
is likely to rise as the population ages. Over the past 15 years,
genetic mechanisms underlying AML have begun to unfold. Additional
research in this area has helped identify key components and
characteristics. Consequently, targeted therapy of AML is receiving much
attention. It is the hope of researchers that as with chronic
myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy
for AML will be discovered. This book adds much to the debate.